Share on StockTwits

Acura Pharmaceuticals (NASDAQ:ACUR) was downgraded by equities researchers at MLV & Co
from a “buy” rating to a “hold” rating in a research report issued on Wednesday, reports. They currently have a $1.00 price target on the stock, down from their previous price target of $2.00. MLV & Co
‘s price target would indicate a potential downside of 20.63% from the company’s current price.

In other Acura Pharmaceuticals news, Director Bruce F. Wesson acquired 80,000 shares of the stock in a transaction dated Friday, May 16th. The shares were purchased at an average price of $1.13 per share, with a total value of $90,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Acura Pharmaceuticals (NASDAQ:ACUR) traded down 15.87% during mid-day trading on Wednesday, hitting $1.06. 223,310 shares of the company’s stock traded hands. Acura Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $2.59. The stock’s 50-day moving average is $1.28 and its 200-day moving average is $1.. The company’s market cap is $51.8 million.

Acura Pharmaceuticals (NASDAQ:ACUR) last announced its earnings results on Monday, May 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.03. On average, analysts predict that Acura Pharmaceuticals will post $-0.16 earnings per share for the current fiscal year.

Separately, analysts at Roth Capital initiated coverage on shares of Acura Pharmaceuticals in a research note on Thursday, May 22nd. They set a “buy” rating and a $2.50 price target on the stock.

Acura Pharmaceuticals, Inc, is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.